|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, July 26, 2017 ) According to the recently published report 'Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1-Pipeline Review H2 2017'; Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) pipeline Target constitutes close to 15 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes.
Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1)-Induced myeloid leukemia cell differentiation protein Mcl-1 also known as Bcl-2-like protein 3 or bcl-2-related protein EATS/Mcl1 is a protein encoded by the MCL1 gene. It is involved in the regulation of apoptosis versus cell survival and in the maintenance of viability but not of proliferation. It mediates its effects by interactions with a number of other regulators of apoptosis.
The report 'Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1-Pipeline Review H2 2017' outlays comprehensive information on the Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) targeted therapeutics complete with analysis by indications stage of development mechanism of action (MoA) route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently The molecules developed by companies in Phase I Preclinical and Discovery stages are 2 4 and 4 respectively. Similarly the universities portfolio in Preclinical and Discovery stages comprises 2 and 3 molecules respectively. Report covers products from therapy areas Oncology and Infectious Disease which include indications Multiple Myeloma (Kahler Disease) Pancreatic Cancer Acute Myelocytic Leukemia (AML Acute Myeloblastic Leukemia) Breast Cancer Colorectal Cancer Head And Neck Cancer Hematological Tumor Malignant Mesothelioma Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Myelodysplastic Syndrome Ovarian Cancer Prostate Cancer Refractory Multiple Myeloma Relapsed Multiple Myeloma and Solid Tumor.
For more information about this report at http://www.reportsweb.com/induced-myeloid-leukemia-cell-differentiation-protein-mcl-1-pipeline-review-h2-2017
Report Scope
- The report provides a snapshot of the global therapeutic landscape for Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1)
- The report reviews Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes product description descriptive MoA R&D brief licensing and collaboration details & other developmental activities
- The report reviews key players involved in Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) targeted therapeutics based on mechanism of action (MoA) route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) targeted therapeutics
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001881473/sample
Reasons to buy
- Gain strategically significant competitor information analysis and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 (Bcl 2 Like Protein 3 or Bcl 2 Related Protein EAT/Mcl1 or BCL2L3 or MCL1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Key Company profiles
AbbVie Inc
Amgen Inc
AstraZeneca Plc
Complix NV
Les Laboratoires Servier SAS
Takeda Pharmaceutical Company Ltd
Warp Drive Bio Inc
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001881473/discount
List of Tables
Number of Products under Development by Stage of Development H2 2017
Number of Products under Development by Therapy Areas H2 2017
Number of Products under Development by Indication H2 2017
Number of Products under Development by Companies H2 2017
Products under Development by Companies H2 2017
Number of Products under Investigation by Universities/Institutes H2 2017
Products under Investigation by Universities/Institutes H2 2017
Number of Products by Stage and Mechanism of Actions H2 2017
Number of Products by Stage and Route of Administration H2 2017
Number of Products by Stage and Molecule Type H2 2017
Pipeline by AbbVie Inc H2 2017
Pipeline by Amgen Inc H2 2017
Pipeline by AstraZeneca Plc H2 2017
Pipeline by Complix NV H2 2017
Pipeline by Les Laboratoires Servier SAS H2 2017
Pipeline by Takeda Pharmaceutical Company Ltd H2 2017
Pipeline by Warp Drive Bio Inc H2 2017
Dormant Products H2 2017
Dormant Products H2 2017 (Contd..1) H2 2017
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001881473/buy/3500
ReportsWeb.com
Rajat Sahni
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
